The molecular profile of breast cancer: primary tumor versus corresponding lymph node metastases

被引:0
|
作者
Floroni, Erwin [1 ]
Ceausu, Amalia Raluca [1 ]
Gaje, Nela Pusa [1 ]
Suciu, Silviu Cristian [1 ]
Cosoroaba, Raluca Mioara [2 ]
Porumb, Anca [3 ]
Popovici, Ramona Amina [2 ]
Raica, Marius [1 ]
机构
[1] Victor Babes Univ Med & Pharm, Angiogenesis Res Ctr Timisoara, Dept Microscop Morphol Histol, Timisoara, Romania
[2] Victor Babes Univ Med & Pharm, Fac Dent Med, Discipline Management Legislat & Commun Dent Med, 2 Eftimie Murgu Sq, Timisoara 300041, Timis County, Romania
[3] Univ Oradea, Fac Med & Pharm, Dept Dent Med, 10 1 December Sq, Oradea 410068, Bihor County, Romania
关键词
breast cancer; immunohistochemistry; molecular classification; lymph node metastases; prognosis; targeted therapy; FACTOR RECEPTOR 2; ESTROGEN-RECEPTOR; PROGNOSTIC IMPACT; HER2; EXPRESSION; E-CADHERIN; DISCORDANCE; CARCINOMA; MARKERS; SITES; KI-67;
D O I
10.47162/RJME.63.2.13
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Breast cancer (BrCa) is the most frequent malignancy in female, and lymph node metastases (LNM) is an important prognostic and therapeutic parameter. The molecular classification is nowadays largely applied to characterize the primary tumors, but few studies focused on the comparison between the molecular profiles of the primary with corresponding LNM. In the current work, we investigated the expression of conventional markers used by molecular classification in both primary tumors and axillary LNM. A series of 156 patients with BrCa was investigated, and from these 80 cases showed LNM. After routine pathological investigation, including the histopathological form and grade, we performed additional step sections from the primary and lymph nodes for immunohistochemistry. All procedures for hormone receptors, human epidermal growth factor receptor 2 (HER2), Ki67, cytokeratin 5 (CK5), epidermal growth factor receptor (EGFR), p53, E-cadherin, and B-cell leukemia/lymphoma-2 (Bcl-2) were performed using the standard automated procedures. We found significant differences between the primary tumors and corresponding LNM in luminal A, luminal B, and basal-like carcinoma. No phenotypical interconversions were noticed in HER2 and unclassified BrCa. Our data demonstrate that in almost 20% of the cases the molecular profile of the primary does not overlap with aspects found in the lymph nodes. Our results strongly suggest performing the molecular classification in both primary tumors and in LNM. Current data suggest that the application of this diagnostic procedure will significantly influence the therapeutic strategy.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [1] Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer
    Zhao, Song
    Xu, Lanwei
    Liu, Wenjun
    Lv, Cuixia
    Zhang, Kai
    Gao, Haidong
    Wang, Jianli
    Ma, Rong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (05): : 5744 - 5748
  • [2] Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases
    Xi, Xun
    Huang, Xing-Wei
    Yuan, Huo-Zhong
    He, Chun
    Ni, Jun
    Yang, Fu-Lan
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [3] Mast cell density in the primary tumor predicts lymph node metastases in patients with breast cancer
    Floroni, Erwin
    Ceausu, Amalia Raluca
    Cosoroaba, Raluca Mioara
    Talpos, Ioana Cristina Niculescu
    Popovici, Ramona Amina
    Gaje, Nela Pusa
    Raica, Marius
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2022, 63 (01) : 129 - 135
  • [4] Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer
    Markiewicz, Aleksandra
    Ahrends, Tomasz
    Welnicka-Jaskiewicz, Marzena
    Seroczynska, Barbara
    Skokowski, Jaroslaw
    Jaskiewicz, Janusz
    Szade, Jolanta
    Biernat, Wojciech
    Zaczek, Anna J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [5] Survival of breast cancer patients according to changes in expression of selected markers between primary tumor and lymph node metastases
    Adamczyk, Agnieszka
    Niemiec, Joanna
    Ambicka, Aleksandra
    Mucha-Malecka, Anna
    Rys, Janusz
    Mitus, Jerzy
    Wysocki, Wojciech M.
    Cichocka, Anna
    Jakubowicz, Jerzy
    BIOMARKERS IN MEDICINE, 2016, 10 (03) : 219 - 228
  • [6] Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up
    Falck, Anna-Karin
    Bendahl, Par-Ola
    Chebil, Gunilla
    Olsson, Hans
    Ferno, Marten
    Ryden, Lisa
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) : 93 - 104
  • [7] St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
    Falck, Anna-Karin
    Ferno, Marten
    Bendahl, Par-Ola
    Ryden, Lisa
    BMC CANCER, 2013, 13
  • [8] Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node
    Liao, Ning
    Li, Cheukfai
    Cao, Li
    Chen, Yanhua
    Ren, Chongyang
    Chen, Xiaoqing
    Mok, Hsiaopei
    Wen, Lingzhu
    Li, Kai
    Wang, Yulei
    Zhang, Yuchen
    Li, Yingzi
    Lv, Jiaoyi
    Cao, Fangrong
    Luo, Yuting
    Li, Hongrui
    Wu, Wendy
    Balch, Charles M.
    Giuliano, Armando E.
    BREAST CANCER, 2023, 30 (01) : 77 - 87
  • [9] Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases
    Yamanouchi, Kosho
    Kuba, Sayaka
    Eguchi, Susumu
    SURGERY TODAY, 2020, 50 (07) : 657 - 663
  • [10] Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy
    Nakamura, Rikiya
    Hayama, Shouko
    Sonoda, Itaru
    Miyaki, Toshiko
    Itami, Makiko
    Yamamoto, Naohito
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (07) : 1513 - 1520